Skip to main content
. 2014 Mar 18;3(3):e154. doi: 10.1038/mtna.2014.4

Figure 3.

Figure 3

Pharmacological effect of hepatic Mogat1 knockdown as the result of a single injection of siRNA-loaded nanoparticles (3 mg/kg) in prediabetic KKAy mice. (a) Mogat1 mRNA levels in the liver after the intravenous injection of nanoparticles loaded with siMogat1 or siLuc (n = 5). (b) Tissue biodistribution of 3H-CHE-labeled nanoparticles in mice. Each mouse received a single injection of nanoparticles loaded with siMogat1 via the tail vein. Tissue biodistribution was assayed 2 hours after treatment (n = 4). (c) Mogat1 mRNA level in other tissues 1 day after the nanoparticle treatment (n = 5). Monitoring of normal glucose levels of (d) prediabetic KKAy (n = 5) and (e) C57BL/6 (n = 7) mice after the nanoparticle treatment. Mean ± SD are shown for all panels. *P < 0.05, **P < 0.01 versus siLuc (a) and nontreatment (c,d; One-way analysis of variance followed by Dunnett's test). siLuc, siRNA against luciferase; siMogat1, siRNA against monoacylglycerol O-acyltransferase 1.